The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC

Wang,Ya-Di; Ha,Min-Wen; Cheng,Jian; Zhang,Wen-Lu; Cong,Xue; Tong,Chun-Yan; Sun,Jing

doi:10.3892/or.2011.1591

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC

Authors:
- Ya-Di Wang
- Min-Wen Ha
- Jian Cheng
- Wen-Lu Zhang
- Xue Cong
- Chun-Yan Tong
- Jing Sun
View Affiliations

Affiliations: Liaoning Medical University, Jinzhou 121000, P.R. China, Department of Oncology, the First Affiliated Hospital of Liaoning Medical University, Jinzhou 121000, P.R. China
Published online on: December 13, 2011 https://doi.org/10.3892/or.2011.1591
Pages: 979-986

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We investigated the correlation between BAG-1 expression and sensitivity to platinum-based chemotherapeutics in patients with non-small cell lung cancer (NSCLC). mRNA and protein expression of BAG-1 in lung tissue of NSCLC postoperative patients (I-IIIA stage) or healthy subjects were detected using reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry, respectively. Cox regression analysis was used to quantify the association of prognostic factors with survival in NSCLC patients. Venous blood samples from patients newly diagnosed with advanced NSCLC (IIIB-IV stage) were collected before chemotherapy to analyze allelic frequency and gene polymorphisms. Compared to healthy controls (11.67%, 14 cases), levels of mRNA and protein of BAG-1 in lung tissues was significantly higher in NSCLC patients (61.67%, 74 cases) (χ2=5.601, P<0.05). Moreover, BAG-1 expression was identified as an independent prognostic factor for survival in NSCLC patients. As time to progression and survival rate was dramatically increased, patients with a positive expression of BAG-1 exhibited a prolonged survival period (TTP, 49.3 months; 5-year survival rat, 16.21%) compared with those without BAG-1 expression (χ2=7.243, P<0.05). Two BAG-1 digestion patterns (CC and CT) were identified and confirmed. patients (77.46%) had a C/C genotype at BAG-1 codon 324, while 22.54% had the C/T genotype. The T/T genotype was not present in these patients. The progression risk of patients carrying the C/C genotype at Bag-1 codon 324 was 1.87 times higher than that of patients carrying the C/T genotype (P<0.001). Follow-up examination showed that the chemotherapeutic sensitivity of patients carrying the C/C genotype was 2.852 times higher than that of patients carrying the C/T genotype (95% CI, 1.133‑7.182; P=0.026). Significant differences were found in the median progression-free survival (PFS) and overall survival (OS) of these two cohorts of patients. Compared to patients carrying the C/T genotype of BAG-1, patients carrying the C/C genotype at Bag-1 codon 324 exhibited better responses to platinum-based chemotherapy. Hence, the expression of BAG-1 was closely associated with the sensitivity to platinum-based chemotherapeutics in NSCLC patients.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol. 6:633–641. 1988.PubMed/NCBI
3	Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol. 11:1866–1872. 1993.PubMed/NCBI
4	Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol. 17:3188–3194. 1999.PubMed/NCBI
5	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
6	Belani CP and Langer C: First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer. 38(Suppl 4): 13–19. 2002. View Article : Google Scholar : PubMed/NCBI
7	Tang SC: BAG-1, an anti-apoptotic tumour marker. IUBMB Life. 53:99–105. 2002. View Article : Google Scholar : PubMed/NCBI
8	Townsend PA, Cutress RI, Sharp A, Brimmell M and Packham G: BAG-1: a multifunctional regulator of cell growth and survival. Biochim Biophys Acta. 1603:83–98. 2003.PubMed/NCBI
9	Liman J, Faida L, Dohm CP, Reed JC, Bahr M and Kermer P: Subcellular distribution affects BAG1 function. Brain Res. 1198:21–26. 2008. View Article : Google Scholar : PubMed/NCBI
10	Cutress RI, Townsend PA, Brimmell M, Bateman AC, Hague A and Packham G: BAG-1 expression and function in human cancer. Br J Cancer. 87:834–839. 2002. View Article : Google Scholar : PubMed/NCBI
11	Rorke S, Murphy S, Khalifa M, Chernenko G and Tang SC: Prognostic significance of BAG-1 expression in non-small cell lung cancer. Int J Cancer. 95:317–322. 2001. View Article : Google Scholar
12	Gautschi O, Hugli B, Ziegler A, et al: Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 51:303–311. 2006. View Article : Google Scholar : PubMed/NCBI
13	Shih CM, Lee YL, Chiou HL, et al: Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer. 52:15–20. 2006. View Article : Google Scholar : PubMed/NCBI
14	Fang S, Jin X, Wang R, et al: Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis. 26:481–486. 2005. View Article : Google Scholar : PubMed/NCBI
15	Humphray SJ, Oliver K, Hunt AR, et al: DNA sequence and analysis of human chromosome 9. Nature. 429:369–374. 2004. View Article : Google Scholar : PubMed/NCBI
16	Silvestrini R, Costa A, Lequaglie C, et al: Bcl-2 protein and prognosis in patients with potentially curable non-small cell lung cancer. Virchows Arch. 432:441–444. 1998. View Article : Google Scholar : PubMed/NCBI
17	Dosaka-Akita H, Katabami M, Hommura H, Fujioka Y, Katoh H and Kawakami Y: Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology. 56:259–264. 1999. View Article : Google Scholar : PubMed/NCBI
18	Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 6:4055–4063. 2000.PubMed/NCBI
19	Takayama S, Sato T, Krajewski S, et al: Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 80:279–284. 1995. View Article : Google Scholar : PubMed/NCBI
20	Takayama S and Reed JC: Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol. 3:E237–E241. 2001. View Article : Google Scholar : PubMed/NCBI
21	Hohfeld J: Regulation of the heat shock conjugate Hsc70 in the mammalian cell: the characterization of the anti-apoptotic protein BAG-1 provides novel insights. Biol Chem. 379:269–274. 1998.PubMed/NCBI
22	Millar EK, Anderson LR, McNeil CM, et al: BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer. 100:123–133. 2009. View Article : Google Scholar : PubMed/NCBI
23	Nadler Y, Camp RL, Giltnane JM, et al: Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res. 10:R352008. View Article : Google Scholar : PubMed/NCBI
24	Liu H, Bai Y, Liu B, et al: The expression of BAG-1 and its clinical significance in human lung cancer. Zhongguo Fei Ai Za Zhi. 11:489–494. 2008.(In Chinese).
25	Tormanen U, Eerola AK, Rainio P, et al: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. 55:5595–5602. 1995.PubMed/NCBI
26	Takahashi N, Yanagihara M, Ogawa Y, Yamanoha B and Andoh T: Down-regulation of Bcl-2-interacting protein BAG-1 confers resistance to anti-cancer drugs. Biochem Biophys Res Commun. 301:798–803. 2003. View Article : Google Scholar : PubMed/NCBI
27	Clemo NK, Collard TJ, Southern SL, et al: BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 29:849–857. 2008. View Article : Google Scholar : PubMed/NCBI
28	Li J, Wang B and Li SN: Advances in the research of single nucleotide polymorphism. J Yunan Normal University (Natural Sciences Edition). 27:40–44. 2007.